Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

× No keyword cloud information.

73 in total

Review 1. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.

Authors: Joost Frans Swart; Daantje Barug; Michelle Möhlmann; Nico M Wulffraat
Journal: Expert Opin Biol Ther Date: 2010-10-28 Impact factor: 4.388

2. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors: S Sawhney; P Woo; K J Murray
Journal: Arch Dis Child Date: 2001-11 Impact factor: 3.791

3. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine.

Authors: A Ravelli; F De Benedetti; S Viola; A Martini
Journal: J Pediatr Date: 1996-02 Impact factor: 4.406

4. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.

Authors: Yukiko Kimura; Paulo Pinho; Gary Walco; Gloria Higgins; Donna Hummell; Ilona Szer; Michael Henrickson; Sandra Watcher; Andreas Reiff
Journal: J Rheumatol Date: 2005-05 Impact factor: 4.666

5. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Authors: P Woo; T R Southwood; A M Prieur; C J Doré; J Grainger; J David; C Ryder; N Hasson; A Hall; I Lemelle
Journal: Arthritis Rheum Date: 2000-08

Review 6. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.

Authors: R Mouy; J L Stephan; P Pillet; E Haddad; P Hubert; A M Prieur
Journal: J Pediatr Date: 1996-11 Impact factor: 4.406

7. Macrophage activation syndrome in a child with systemic juvenile rheumatoid arthritis.

Authors: Mina Hur; Young Chul Kim; Kyu Man Lee; Kwang Nam Kim
Journal: J Korean Med Sci Date: 2005-08 Impact factor: 2.153

8. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors: Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal: Lancet Date: 2008-07-14 Impact factor: 79.321

9. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.

Authors: Patricia Woo; Nicholas Wilkinson; Anne-Marie Prieur; Taunton Southwood; Valentina Leone; Polly Livermore; Helena Wythe; David Thomson; Tadamitsu Kishimoto
Journal: Arthritis Res Ther Date: 2005-09-15 Impact factor: 5.156

10. Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis.

Authors: Miguel De La Torre; Luis Arboleya; Sergio Pozo; Jesús Pinto; Julio Velasco
Journal: NDT Plus Date: 2011-03-02

24 in total

Review 1. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.

Authors: Sathish Kumar
Journal: Indian J Pediatr Date: 2016-02-26 Impact factor: 1.967

Review 2. Cyclosporine for Systemic Onset Juvenile Idiopathic Arthritis: Current Stand and Future Directions.

Authors: Narendra Kumar Bagri
Journal: Indian J Pediatr Date: 2019-06-01 Impact factor: 1.967

3. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment.

Authors: Panayiota Nalbanti; Florentia Kanakoudi-Tsakalidou; Maria Trachana; Polyxeni Pratsidou-Gertsi; Evangelia Farmaki; Panagiotis Bamidis; Fotios Papachristou
Journal: Rheumatol Int Date: 2018-05-29 Impact factor: 2.631

Review 4. Intra-articular glucocorticoid injections and their effect on hypothalamic-pituitary-adrenal (HPA)-axis function.

Authors: Philip C Johnston; M Cecilia Lansang; Soumya Chatterjee; Laurence Kennedy
Journal: Endocrine Date: 2014-09-03 Impact factor: 3.633

Review 5. Treatment in juvenile rheumatoid arthritis and new treatment options.

Authors: Özgür Kasapçopur; Kenan Barut
Journal: Turk Pediatri Ars Date: 2015-03-01

Review 6. Regulating against the dysregulation: new treatment options in autoinflammation.

Authors: Tilmann Kallinich
Journal: Semin Immunopathol Date: 2015-06-10 Impact factor: 9.623

Review 7. Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors: Ezgi Deniz Batu
Journal: Rheumatol Int Date: 2018-10-01 Impact factor: 2.631

8. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors: Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal: Clin Trials Date: 2018-03-15 Impact factor: 2.486

Review 9. Etanercept: a review of its use in autoimmune inflammatory diseases.

Authors: Lesley J Scott
Journal: Drugs Date: 2014-08 Impact factor: 9.546

Review 10. Judicious use of biologicals in juvenile idiopathic arthritis.

Authors: Yongdong Zhao; Carol Wallace
Journal: Curr Rheumatol Rep Date: 2014-11 Impact factor: 4.592